Escitalopram

Brand names: Lexapro · Active ingredient: Escitalopram Oxalate

In short: Escitalopram Capsules are indicated for the treatment of: Major depressive disorder (MDD) in adults younger than 65 years of age and pediatric patients 12 years of age and older. Generalized anxiety disorder (GAD) in adults younger than 65 years of age .

Forms & strengthsCapsules: 15 mg of escitalopram available as hard shell gelatin capsules, with “ALM” printed axially on the light blue opaque cap and “795” printed axially on the blue opaque body. All printing is in black ink.
LabelAlmatica Pharma LLC
Label updatedNov 11, 2026

What is Escitalopram used for?

Escitalopram Capsules are indicated for the treatment of:

Major depressive disorder (MDD) in adults younger than 65 years of age and pediatric patients 12 years of age and older.

Generalized anxiety disorder (GAD) in adults younger than 65 years of age .

Additional pediatric use information is approved for AbbVie Inc.’s LEXAPRO (escitalopram) tablets and LEXAPRO (escitalopram) oral solution. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.

⚠ Boxed warning (FDA's strongest warning)

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors

.

Escitalopram dosage

Escitalopram Capsules are only available in a 15 mg strength. Use another escitalopram product for initial dosage, dosage titration, administration of dosages other than 15 mg once daily, and to taper during discontinuation . Refer to the Prescribing Information of other escitalopram products for the recommended dosage for those products.

Escitalopram Capsules may be initiated in patients experiencing unfavorable tolerability to a 20 mg escitalopram dosage .

Escitalopram Capsules are not indicated in geriatric patients. Avoid use of Escitalopram Capsules in geriatric patients because the recommended dosage in these patients cannot be achieved with the Escitalopram Capsules 15 mg strength .

Escitalopram Capsules are not recommended in patients with hepatic impairment because the recommended dosage in such patients cannot be achieved with the Escitalopram Capsules 15 mg strength .

The recommended starting dosage of escitalopram for MDD in adults younger than 65 years of age and pediatric patients 12 years of age and older is 10 mg orally once daily. Use another escitalopram product for dosage initiation.

Based on clinical response and tolerability, the dosage may be increased to the maximum recommended dosage of 20 mg once daily of another escitalopram product after at least 1 week in adults younger than 65 years of age and after 3 weeks in pediatric patients 12 years of age and older. Escitalopram Capsules 15 mg orally once daily may be initiated in patients experiencing unfavorable tolerability to a 20 mg escitalopram dosage.

The recommended starting dosage of escitalopram for GAD in adults younger than 65 years of age is 10 mg orally once daily. Use another escitalopram product for dosage initiation.

Based on clinical response and tolerability, the dosage may be increased to the maximum recommended dosage of 20 mg once daily of another escitalopram product after at least 1 week in adults younger than 65 years of age. Escitalopram Capsules 15 mg orally once daily may be initiated in patients experiencing unfavorable tolerability to a 20 mg escitalopram dosage.

Additional pediatric use information is approved for AbbVie Inc.’s LEXAPRO (escitalopram) tablets and LEXAPRO (escitalopram) oral solution. However, due to AbbVie Inc. ’s marketing exclusivity rights, this drug product is not labeled with that information.

Administer Escitalopram Capsules orally once daily, in the morning or evening, with or without food . Swallow capsules whole; do not open, crush, or chew.

Prior to initiating treatment with Escitalopram Capsules or another antidepressant, screen patients for a personal family history of bipolar disorder, mania, or hypomania . …

How to take Escitalopram — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behaviors

Advise patients and caregivers to look for the emergence of suicidal ideation and behavior, especially early during treatment and when the dosage is adjusted up or down, and instruct them to report such symptoms to their healthcare provider .

Serotonin Syndrome

Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of Escitalopram Capsules with other serotonergic drugs including triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Instruct patients to contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome .

Discontinuation Syndrome

Advise patients not to abruptly discontinue Escitalopram Capsules and to discuss any tapering regimen with their healthcare provider. …

Warnings & precautions

Do not take this medicine if: Escitalopram Capsules are contraindicated in patients:

Taking, or within 14 days of stopping, MAOIs, including linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome .

Taking pimozide because of the risk of QT prolongation .

With known hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in Escitalopram Capsules.

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in the antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1.

Age Range | Drug-Placebo Difference in Number of

Patients of Suicidal Thoughts and Behaviors

per 1000 Patients Treated

Increases Compared to Placebo

<18 years old | 14 additional patients

18 to 24 years old | 5 additional patients

Decreases Compared to Placebo

25 to 64 years old | 1 fewer patient

≥65 years old | 6 fewer patients

It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. …

Escitalopram side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Suicidal Thoughts and Behaviors in Adolescents and Young Adults

Serotonin Syndrome

Discontinuation Syndrome

Seizures

Activation of Mania or Hypomania

Hyponatremia

Increased Risk of Bleeding

Interference with Cognitive and Motor Performance

Angle Closure Glaucoma

Use in Patients with Concomitant Illness

Sexual Dysfunction

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The safety of Escitalopram Capsules 15 mg once daily for the treatment of major depressive disorder (MDD) in adults younger than 65 years of age and pediatric patients 12 years of age and older and for the treatment of generalized anxiety disorder (GAD) in adults younger than 65 years of age is based upon adequate and well-controlled studies of another escitalopram product with dosing ranging from 10 to 20 mg once daily. The results of these adequate and well-controlled studies are presented below.

Clinical Trial Data Sources

Adults

Adverse reaction data in adults with MDD were collected from 715 patients who were exposed to escitalopram and from 592 patients who were exposed to placebo in double-blind, placebo-controlled trials. …

Drug interactions

Table 6 presents clinically important drug interactions with Escitalopram Capsules.

Monoamine Oxidase Inhibitors (MAOIs)

Prevention or Management | Escitalopram Capsules are contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue .

Mechanism and Clinical Effect(s) | Concomitant use of SSRIs, including Escitalopram Capsules, and MAOIs increases the risk of serotonin syndrome.

Pimozide

Prevention or Management | Escitalopram Capsules are contraindicated in patients taking pimozide .

Mechanism and Clinical Effect(s) | Concomitant use of racemic citalopram with pimozide increases plasma concentrations of pimozide, a drug with a narrow therapeutic index, and may increase the risk of QT prolongation and/or ventricular arrhythmias compared to use of racemic citalopram alone. The mechanism of this pharmacodynamic interaction is not known .

Other

Serotonergic Drugs

Prevention or Management | Monitor patients for signs and symptoms of serotonin syndrome, particularly during escitalopram initiation and dosage increases. If serotonin syndrome occurs, consider discontinuation of Escitalopram Capsules and/or concomitant serotonergic drugs . …

About this medicine

Escitalopram Capsules contain escitalopram, a selective serotonin reuptake inhibitor (SSRI), present as escitalopram oxalate salt. Escitalopram is the pure S- enantiomer (single isomer) of the racemic bicyclic phthalane derivative citalopram. Escitalopram oxalate is designated S-(+)-1-[3(dimethyl-amino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate with the following structural formula:

The molecular formula is C20H21FN2O • C2H2O4 and the molecular weight is 414.43. Escitalopram oxalate occurs as a fine, white to slightly yellow powder and is freely soluble in methanol and in dimethyl sulphoxide, sparingly soluble in water and in alcohol, very slightly soluble in ethyl acetate and in isopropyl alcohol, and insoluble in heptane.

Escitalopram Capsules are intended for oral administration and are available only in a 15 mg strength. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c0401570-a3b0-bef2-7365-c23dc952b8b6. Read the full official label on DailyMed.

Related medicines

Sertraline Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone Venlafaxine